Cargando…
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
BACKGROUND: The clinical significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety and efficacy of PD-1 inhibitors with toripalimab, camrelizumab or sintilimab for Chinese hepatocellular carcinoma (HCC) pat...
Autores principales: | Chen, Jinzhang, Hu, Xiaoyun, Li, Qi, Dai, Wencong, Cheng, Xiao, Huang, Wei, Yu, Wenxuan, Chen, Mian, Guo, Yabing, Yuan, Guosheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576044/ https://www.ncbi.nlm.nih.gov/pubmed/33241036 http://dx.doi.org/10.21037/atm-20-6063 |
Ejemplares similares
-
Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Yuan, Guosheng, et al.
Publicado: (2020) -
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022) -
Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study
por: Yuan, Guosheng, et al.
Publicado: (2021) -
Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients
por: Yuan, Guosheng, et al.
Publicado: (2021) -
Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)